SeraCare Announces Acquisition of Serologicals' Celliance Subsidiary Assets
2005年11月29日 - 9:00PM
PRニュース・ワイアー (英語)
OCEANSIDE, Calif., Nov. 29 /PRNewswire-FirstCall/ -- SeraCare Life
Sciences, Inc. (NASDAQ:SRLS), today announced that it has signed an
agreement to purchase the Milford, MA diagnostic manufacturing
facilities and product lines of the Celliance subsidiary of
Serologicals Corporation (NASDAQ:SERO) for $3.7 million in cash
plus the assumption of certain liabilities. Michael F. Crowley,
Jr., President and CEO of SeraCare Life Sciences said, "This
acquisition will increase our portfolio of products in the areas of
molecular diagnostic reagents, diagnostic intermediates and
substrates. In connection with this acquisition, we will assume the
lease on Celliance's state of the art manufacturing, storage and
distribution facility located near our West Bridgewater
manufacturing site. We believe the proximity of these two
diagnostic manufacturing facilities will allow us to achieve
synergies in the areas of manufacturing, staffing and
distribution." SeraCare expects the acquisition to be accretive to
earnings by the first fiscal quarter following the closing of the
acquisition, which, subject to the satisfaction of customary
closing conditions, is expected to be completed in January 2006.
About SeraCare Life Sciences SeraCare Life Sciences, Inc. is a
manufacturer and supplier of biological materials and services
essential for the use and manufacture of diagnostic tests and the
discovery, development and commercial production of
pharmaceuticals. The Company's offerings include plasma-based
therapeutic products, diagnostic products and reagents, cell
culture products, specialty plasmas, in vitro stabilizers, and the
Global Repository(R), comprised of clinical samples (DNA, RNA,
tissue, and serum) for use in the drug discovery and development
processes. SeraCare is headquartered in Oceanside, CA, and
maintains facilities in Cambridge and West Bridgewater, MA;
Frederick and Gaithersburg, MD; and Hatboro, PA. For more
information please visit http://www.seracare.com/ or divisional web
sites at http://www.bbii.com/ and http://www.getdna.com/. Safe
Harbor For Forward-Looking Statements Certain statements contained
in this press release may be deemed to be forward looking
statements under federal securities laws, and the Company intends
that such forward looking statements be subject to the safe harbor
created thereby. Such statements include the Company's expectation
that (i) the asset acquisition will increase its portfolio of
products in the areas of molecular diagnostic reagents, diagnostic
intermediates and substrates (ii) the proximity of the Celliance
manufacturing facility and the Company's West Bridgewater
manufacturing facility will allow the Company to achieve
efficiencies in the areas of manufacturing, staffing and
distribution, (iii) the asset acquisition will be accretive to the
Company's earnings by the first fiscal quarter following the
closing of the acquisition, and (iv) the closing of the acquisition
will be completed in January 2006. The Company cautions that these
statements are qualified by important factors that could cause
actual results to differ materially from those reflected by the
forward- looking statements. Such factors include, but are not
limited to (i) the ability of the parties to the acquisition
agreement to timely satisfy each of the conditions to closing, (ii)
the Company's ability to integrate the acquired operations into its
own, (iii) the Company's ability to retain the customers from the
acquired operations, and (iv) the Company's access to adequate
blood and plasma raw materials on terms consistent with its
existing contracts. Information on these and additional factors
that could affect the Company and its financial results is included
in the Company's report on Form 10-K for the year ended September
30, 2004 filed with the Securities and Exchange Commission (SEC) as
well as the Company's other public filings with the SEC. The
Company undertakes no obligation to publicly update or revise any
forward looking statements, whether as a result of new information,
future events or otherwise. DATASOURCE: SeraCare Life Sciences,
Inc. CONTACT: Tim Ryan of The Trout Group, +1-212-477-9007, x24, or
, for SeraCare Life Sciences, Inc. Web site:
http://www.seracare.com/ http://www.bbii.com/
http://www.getdna.com/
Copyright
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 5 2024 まで 6 2024
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 6 2023 まで 6 2024